16 February 2016 Oryzon Genomics Announces Presentation and Panel Discussion at the SACHS Associates 1st Annual Neuroscience BioPartnering & Investment Forum
29 January 2016 Oryzon Receives Approval in Spain to Initiate Phase I for ORY-2001 for Alzheimer’s Disease
29 December 2015 Oryzon Genomics Receives 1.3M USD Public Aids to Advance Development of its Epigenetic Inhibitors
16 December 2015 ORYZON Files Clinical Trial Application in Spain for Phase I Study with ORY-2001 for Alzheimer’s Disease
10 November 2015 Oryzon Genomics Announces First Patient Dosed in Phase I Extension Cohort of ORY-1001
4 November 2015 ORYZON Announces the Appointment of Mr. Antonio Fornieles, Ms. Isabel Aguilera and Mr. Ramon Adell as Independent Directors